Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
|
|
NORTHWEST BIOTHERAPEUTICS INC (NWBO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/08/2013 |
8-K
| Quarterly results|
Docs:
|
"NW Bio 2012 ANNUAL REPORT SHOWS STRONG PROGRESS AND ENHANCEMENT OF LEADERSHIP POSITION BETHESDA, MD, April 8, 2013 -- Northwest Biotherapeutics , a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, filed its annual report on Form 10K today, reporting its financial results for the year ended December 31, 2012. The report also shows strong progress in all areas of the Company’ s operations, enhancing the Company’ s leadership position in immune therapies for cancer. Year End 2012 Financial Results During the twelve months ended December 31, 2012, the company used $22.8 million in cash for operating activities, compared to $14.7 million in cash for operating activities during the twelve months ended December 31, 2011. The Company incurred an overall..." |
|
|
|